Pain Research and Management (Jan 2015)

A Prospective Multicentre Study to Evaluate the Efficacy and Tolerability of Osmotic Release Oral System (Oros®) Hydromorphone in Opioid-Naive Cancer Patients: Results of the Korean South West Oncology Group Study

  • Eun-Kee Song,
  • Hyunjeong Shim,
  • Hye-Suk Han,
  • DerSheng Sun,
  • Soon-Il Lee,
  • Myung Hee Kang,
  • KyuTaek Lee,
  • DoYeun Cho,
  • In Sung Cho,
  • Suk Young Park,
  • Samyong Kim,
  • Chang-Yeol Yim

DOI
https://doi.org/10.1155/2015/458389
Journal volume & issue
Vol. 20, no. 6
pp. 293 – 299

Abstract

Read online

BACKGROUND: Osmotic release oral system (OROS®) hydromorphone is a potent, long-acting opioid analgesic, effective and safe for controlling cancer pain in patients who have received other strong opioids. To date, few studies have examined the efficacy of hydromorphone for pain relief in opioid-naive cancer patients.